{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:39Z","timestamp":1740147759475,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11886-021-01627-8","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T20:55:33Z","timestamp":1642107333000},"page":"87-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Monotherapy with a P2Y12 Inhibitor for Secondary Prevention in Patients with Established Atherosclerosis"],"prefix":"10.1007","volume":"24","author":[{"given":"Juan J.","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis E.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6384-8768","authenticated-orcid":false,"given":"Oscar C.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan J.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Libby P, Buring J, Badimon L, Hansson G, Deanfield J, Bittencourt M, et al. Atherosclerosis. Nature Reviews Disease Primers. 2019;5(1).","key":"1627_CR1","DOI":"10.1038\/s41572-019-0106-z"},{"issue":"7347","key":"1627_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature10146","volume":"473","author":"P Libby","year":"2011","unstructured":"Libby P, Ridker P, Hansson G. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317\u201325.","journal-title":"Nature"},{"issue":"15","key":"1627_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1001\/jama.2021.0716","volume":"325","author":"H Kamran","year":"2021","unstructured":"Kamran H, Jneid H, Kayani W, Virani S, Levine G, Nambi V, et al. Oral antiplatelet therapy after acute coronary syndrome. JAMA. 2021;325(15):1545.","journal-title":"JAMA"},{"doi-asserted-by":"crossref","unstructured":"Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: a report From the American Heart Association. Circulation 2020;141:e139.","key":"1627_CR4","DOI":"10.1161\/CIR.0000000000000746"},{"doi-asserted-by":"publisher","unstructured":"Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849\u201360.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(09)60503-1.","key":"1627_CR5","DOI":"10.1016\/S0140-6736(09)60503-1"},{"issue":"21","key":"1627_CR6","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1001\/jama.2021.2126","volume":"325","author":"T Polonsky","year":"2021","unstructured":"Polonsky T, McDermott M. Lower extremity peripheral artery disease without chronic limb-threatening ischemia. JAMA. 2021;325(21):2188.","journal-title":"JAMA"},{"doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Chiarito M, Sanz-S\u00e1nchez J, Cannata F, Cao D, Sturla M, Panico C, Godino C, Regazzoli D, Reimers B, De Caterina R, Condorelli G, Ferrante G, Stefanini GG. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395(10235):1487\u20131495.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(20)30315-9. PMID: 32386592. This systematic review and meta-analysis evidenced P2Y12 inhibitors have a lower risk of acute myocardial infarction compared to aspirin alone in secondary prevention. This supports evidence for a broader use in continuing P2Y12 inhibitors in preference to aspirin as secondary prevention in acute coronary syndrome.","key":"1627_CR7","DOI":"10.1016\/S0140-6736(20)30315-9"},{"doi-asserted-by":"crossref","unstructured":"Fihn S, Blankenship J, Alexander K, Bittl J, Byrne J, Fletcher B, Fonarow G, Lange R, Levine G, et al. 2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol.\u00a02014;64(18):1929\u20131949.","key":"1627_CR8","DOI":"10.1161\/CIR.0000000000000095"},{"issue":"16","key":"1627_CR9","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Sch\u00fcpke","year":"2019","unstructured":"Sch\u00fcpke S, Neumann F, Menichelli M, Mayer K, Bernlochner I, W\u00f6hrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524\u201334.","journal-title":"N Engl J Med"},{"key":"1627_CR10","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"D Bhatt","year":"2006","unstructured":"Bhatt D, Fox K, Hacke W, Berger P, Black H, Boden W, Cacoub P, Cohen E, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706\u201317.","journal-title":"N Engl J Med"},{"doi-asserted-by":"publisher","unstructured":"Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM; CADET Study Investigators. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004 Nov;2(11):1934\u201340.\u00a0https:\/\/doi.org\/10.1111\/j.1538-7836.2004.01017.x. PMID: 15550024.","key":"1627_CR11","DOI":"10.1111\/j.1538-7836.2004.01017.x"},{"doi-asserted-by":"publisher","unstructured":"Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J. 2004;38(6):353\u20136.\u00a0https:\/\/doi.org\/10.1080\/14017430410024324. PMID: 15804802.","key":"1627_CR12","DOI":"10.1080\/14017430410024324"},{"issue":"16","key":"1627_CR13","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1001\/jama.2018.3197.PMID:29710164;PMCID:PMC5933396","volume":"319","author":"Q Zhao","year":"2018","unstructured":"Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, Wang X. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial. JAMA. 2018;319(16):1677\u201386. https:\/\/doi.org\/10.1001\/jama.2018.3197. PMID: 29710164; PMCID: PMC5933396.","journal-title":"JAMA"},{"doi-asserted-by":"publisher","unstructured":"Schunkert H, Boening A, von Scheidt M, Lanig C, Gusmini F, de Waha A, Kuna C, Fach A, Grothusen C, Oberhoffer M, Knosalla C, Walther T, Danner BC, Misfeld M, Zeymer U, Wimmer-Greinecker G, Siepe M, Grubitzsch H, Joost A, Schaefer A, Conradi L, Cremer J, Hamm C, Lange R, Radke PW, Schulz R, Laufer G, Grieshaber P, Pader P, Attmann T, Schmoeckel M, Meyer A, Ziegelh\u00f6ffer T, Hambrecht R, Kastrati A, Sandner SE. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. Eur Heart J. 2019;40(29):2432\u20132440.\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehz185. PMID: 31145798.","key":"1627_CR14","DOI":"10.1093\/eurheartj\/ehz185"},{"doi-asserted-by":"publisher","unstructured":"Vranckx P, Valgimigli M, J\u00fcni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, M\u00f6llmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S. GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940\u2013949.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(18)31858-0. Epub\u00a027 Aug 2018. PMID: 30166073.","key":"1627_CR15","DOI":"10.1016\/S0140-6736(18)31858-0"},{"key":"1627_CR16","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma S, Cohen D, Angiolillo D, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381:2032\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1908419.","journal-title":"N Engl J Med"},{"issue":"23","key":"1627_CR17","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"B Kim","year":"2020","unstructured":"Kim B, Hong S, Cho Y, Yun K, Kim Y, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome. JAMA. 2020;323(23):2407.","journal-title":"JAMA"},{"issue":"23","key":"1627_CR18","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"B Kim","year":"2020","unstructured":"Kim B, Hong S, Cho Y, Yun K, Kim Y, Suh Y, et al. Effect of inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention. JAMA. 2020;323(23):2407.","journal-title":"JAMA"},{"issue":"24","key":"1627_CR19","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"J Hahn","year":"2019","unstructured":"Hahn J, Song Y, Oh J, Chun W, Park Y, Jang W, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention. JAMA. 2019;321(24):2428.","journal-title":"JAMA"},{"doi-asserted-by":"crossref","unstructured":"Kogame N, Guimar\u00e3es P, Modolo R, De Martino F, Tinoco J, Ribeiro E, et al. Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD. JACC: Cardiovascular Interventions. 2020;13(19):2251\u20132262.","key":"1627_CR20","DOI":"10.1016\/j.jcin.2020.06.023"},{"doi-asserted-by":"publisher","unstructured":"\u2022 Koo B. Kang J. Park K. Rhee T. Yang H. Won K. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 2021.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(21)01063-1. Findings from this study show the potential benefits of clopidogrel versus aspirin in monotherapy following dual therapy after percutaneous coronary intervention where the risk of bleeding is lower.","key":"1627_CR21","DOI":"10.1016\/S0140-6736(21)01063-1"},{"key":"1627_CR22","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"D Kleindorfer","year":"2021","unstructured":"Kleindorfer D, Towfighi A, Chaturvedi S, Cockroft K, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2021;52:e364\u2013467.","journal-title":"Stroke"},{"doi-asserted-by":"publisher","unstructured":"Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331\u20137.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(04)16721-4. PMID: 15276392.","key":"1627_CR23","DOI":"10.1016\/S0140-6736(04)16721-4"},{"doi-asserted-by":"crossref","unstructured":"\u2022 Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207\u201317. This trial demonstrated that dual antiplatelet therapy with ticagrelor plus aspirin had a lower risk of recurrent stroke after mild-to-moderate ischemic stroke or high risk TIA compared to aspirin monotherapy. This provides evidence for the use of an alternative P2Y12 inhibitor, particularly in individuals who exhibit clopidogrel resistance.","key":"1627_CR24","DOI":"10.1056\/NEJMoa1916870"},{"key":"1627_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11886-021-01581-5","volume":"23","author":"K Marsden","year":"2021","unstructured":"Marsden K, Mak HY, Crooks CP, et al. A clinical update on antiplatelet therapy in secondary prevention of ischemic stroke. Curr Cardiol Rep. 2021;23:145. https:\/\/doi.org\/10.1007\/s11886-021-01581-5.","journal-title":"Curr Cardiol Rep"},{"issue":"11","key":"1627_CR26","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","volume":"69","author":"M Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman M, Gornik H, Barrett C, Barshes N, Corriere M, Drachman D, et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease. J Am Coll Cardiol. 2017;69(11):e71\u2013126.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1627_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1611688","volume":"376","author":"W Hiatt","year":"2017","unstructured":"Hiatt W, Fowkes F, Heizer G, Berger J, Baumgartner I, Held P, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376(1):32\u201340.","journal-title":"N Engl J Med"},{"issue":"9038","key":"1627_CR28","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(96)09457-3.","journal-title":"Lancet"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01627-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-021-01627-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01627-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T06:22:47Z","timestamp":1646634167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-021-01627-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1627"],"URL":"https:\/\/doi.org\/10.1007\/s11886-021-01627-8","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"type":"print","value":"1523-3782"},{"type":"electronic","value":"1534-3170"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"5 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}